CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

R. C. Prins, R. T. Burke, J. W. Tyner, B. J. Druker, M. M. Loriaux, S. E. Spurgeon

Research output: Contribution to journal › Letter › peer-review

46 Scopus citations

Fingerprint

Dive into the research topics of 'CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway'. Together they form a unique fingerprint.